The estimated Net Worth of Klaus R Dr Veitinger is at least $5.23 Million dollars as of 1 November 2019. Klaus Veitinger owns over 5,250 units of Tricida Inc stock worth over $5,659 and over the last 12 years he sold TCDA stock worth over $4,891,227. In addition, he makes $338,000 as Independent Chairman of the Board at Tricida Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Klaus Veitinger TCDA stock SEC Form 4 insiders trading
Klaus has made over 32 trades of the Tricida Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 5,250 units of TCDA stock worth $204,120 on 1 November 2019.
The largest trade he's ever made was selling 66,300 units of Tricida Inc stock on 28 March 2019 worth over $2,266,797. On average, Klaus trades about 2,988 units every 42 days since 2012. As of 1 November 2019 he still owns at least 51,444 units of Tricida Inc stock.
You can see the complete history of Klaus Veitinger stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Klaus Veitinger biography
Dr. Klaus R. Veitinger M.D., Ph.D. serves as Independent Chairman of the Board of the Company. Dr. Veitinger has served as a Venture Partner with OrbiMed Advisors LLC, an affiliate of one of our principal stockholders, since October 2007. Prior to OrbiMed Advisors, Dr. Veitinger was a Member of the Executive Board of Schwarz Pharma AG and the Chief Executive Officer of Schwarz Pharma, Inc. with responsibility for the U.S. and Asia businesses. Dr. Veitinger has served on the boards of public companies, including Intercept Pharmaceuticals, Inc. from August 2012 until July 2016 and Relypsa, Inc. from October 2010 until June 2015, and currently serves on the board of scPharmaceuticals, Inc. since November 2017. Dr. Veitinger currently serves on the boards of directors of the following private companies: Neurogastrx, Inc. and Promentis Pharmaceuticals, Inc. For seven years he was a Director of PhRMA. Dr. Veitinger received his M.D. and his Ph.D. from the University of Heidelberg. He earned his M.B.A. at INSEAD in France.
What is the salary of Klaus Veitinger?
As the Independent Chairman of the Board of Tricida Inc, the total compensation of Klaus Veitinger at Tricida Inc is $338,000. There are 9 executives at Tricida Inc getting paid more, with Gerrit Klaerner having the highest compensation of $10,168,700.
How old is Klaus Veitinger?
Klaus Veitinger is 58, he's been the Independent Chairman of the Board of Tricida Inc since 2015. There are 6 older and 10 younger executives at Tricida Inc. The oldest executive at Tricida Inc is Robert Alpern, 69, who is the Independent Director.
Insiders trading at Tricida Inc
Over the last 6 years, insiders at Tricida Inc have traded over $198,373,537 worth of Tricida Inc stock and bought 7,174,449 units worth $105,536,837 . The most active insiders traders include David P Bonita, Advisors Llc Orbi Med Capit..., and Healthcare Capital Partners.... On average, Tricida Inc executives and independent directors trade stock every 8 days with the average trade being worth of $22,553. The most recent stock trade was executed by Robert J Alpern on 23 November 2022, trading 131,879 units of TCDA stock currently worth $27,695.
What does Tricida Inc's logo look like?
Complete history of Klaus Veitinger stock trades at Intercept Pharmaceuticals Inc, scPharmaceuticals Inc, and Tricida Inc
Tricida Inc executives and stock owners
Tricida Inc executives and other stock owners filed with the SEC include:
-
Gerrit Klaerner,
President, Chief Executive Officer, Director -
Dawn Parsell,
Executive Vice President - Clinical Development -
Geoffrey Parker,
Chief Financial Officer, Executive Vice President -
Edward Hejlek,
Senior Vice President -
Dr. Gerrit Klaerner Ph.D.,
Founder, Pres, CEO & Exec. Director -
Dr. Dawn Parsell Ph.D.,
Exec. VP of Clinical Devel. -
Geoffrey M. Parker,
COO, CFO & Exec. VP -
Robert L. McKague J.D.,
Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer -
Dr. Wilhelm Stahl,
Exec. VP & CTO -
Klaus Veitinger,
Independent Chairman of the Board -
David Bonita,
Independent Director -
Kathryn Falberg,
Independent Director -
David Hirsch,
Independent Director -
Sandra Coufal,
Independent Director -
Robert Alpern,
Independent Director -
Marc Cobo,
Senior Vice President - Finance, Chief Accounting Officer -
Robert McKague,
Executive Vice President, General Counsel, Secretary -
Edward J. Hejlek Esq., J.D.,
Exec. VP of Intellectual Property -
Jackie Cossmon,
VP of Investor Relations & Communications -
Annie Yoshiyama,
VP of Fin. & Chief Accounting Officer -
Claire Lockey,
Chief Dev. Officer and Sr. VP -
Brian M.Sibling Capital Fun...,
-
Brian M.Sibling Capital Fun...,
-
Brian M.Sibling Capital Ven...,
-
Beek Jeroen B Van,
Chief Comm Officer and Sr VP -
Steffen Pietzke,
VP Fin & Chief Acct Officer -
Capital Partners Ii, Llc Lo...,
-
Advisors Llc Orbi Med Capit...,
-
Harbor Master Investors (Ca...,
10% owner -
Wilhelm Stahl,
EVP, Chief Tech Officer -
Brian M.Sibling Capital Ven...,
-
Susannah Cantrell,
EVP, Chief Comm. Officer -
Brian M.Sibling Capital Fun...,
-
Brian M.Sibling Capital Fun...,
-
Annie Yoshiyama,
Senior VP, Finance and CAO -
Healthcare Capital Partners...,